ATE120091T1 - Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz. - Google Patents
Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz.Info
- Publication number
- ATE120091T1 ATE120091T1 AT89112463T AT89112463T ATE120091T1 AT E120091 T1 ATE120091 T1 AT E120091T1 AT 89112463 T AT89112463 T AT 89112463T AT 89112463 T AT89112463 T AT 89112463T AT E120091 T1 ATE120091 T1 AT E120091T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- vip
- hydrophobic
- conjugates
- motions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL8705588A IL87055A (en) | 1988-07-08 | 1988-07-08 | Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE120091T1 true ATE120091T1 (de) | 1995-04-15 |
Family
ID=11059032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT89112463T ATE120091T1 (de) | 1988-07-08 | 1989-07-07 | Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5147855A (de) |
EP (1) | EP0354992B1 (de) |
JP (1) | JP2682702B2 (de) |
AT (1) | ATE120091T1 (de) |
DE (1) | DE68921814T2 (de) |
ES (1) | ES2072875T3 (de) |
IL (1) | IL87055A (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447912A (en) * | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
US5236904A (en) * | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
NZ237899A (en) * | 1990-04-25 | 1997-03-24 | Vivus Inc Substituted For Alza | An apparatus comprising a shaft and a therapeutic composition; suitable to treat erectile dysfunction by insertion in the urethra |
ES2063406T3 (es) * | 1990-06-26 | 1995-01-01 | Sanwa Kagaku Kenkyusho Co | Procedimiento para la preparacion de analogos de polipeptido intestinal vasoactivo. |
IL99924A (en) * | 1991-10-31 | 1995-12-31 | Yeda Res & Dev | Derivatives of structurally modified vip and pharmaceutical compositions containing them |
US5998368A (en) * | 1991-10-31 | 1999-12-07 | Yeda Research And Development Co. Ltd. | Derivatives of structurally modified VIP and pharmaceutical compositions containing them |
JP2704214B2 (ja) * | 1991-12-10 | 1998-01-26 | タノックス バイオシステムズ インコーポレイテッド | 非対合システイン残基を有するサイトカイン及びその結合体 |
BR9203277A (pt) * | 1992-08-21 | 1994-03-01 | Cesar Roberto Dias Nahoum | Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao |
US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
US5382392A (en) * | 1993-02-05 | 1995-01-17 | Alliedsignal Inc. | Process for fabrication of carbon fiber-reinforced carbon composite material |
US5972883A (en) * | 1993-03-16 | 1999-10-26 | Yeda Research And Development Co. Ltd. | Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof |
WO1994022460A1 (en) * | 1993-04-05 | 1994-10-13 | University Patents, Inc. | Diagnosis and treatment of erectile dysfunction |
US5333621A (en) * | 1993-05-28 | 1994-08-02 | Eric Denzer | Condom with transdermal vasodilator |
US6007836A (en) * | 1993-05-28 | 1999-12-28 | Vericade, Inc. | Transdermal vasodilator |
IL118003A0 (en) | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
KR20010021625A (ko) | 1997-07-09 | 2001-03-15 | 추후보정 | 개선된 남성발기 기능장애 치료방법 및 그 조성물 |
US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
US6828304B1 (en) | 2000-07-31 | 2004-12-07 | Dabur Research Foundation | Peptides for treatment of cancer |
WO2002010193A1 (en) * | 2000-07-31 | 2002-02-07 | Dabur Research Foundation | Lipid-peptide conjugates for treatment of cancer |
WO2002043746A2 (en) | 2000-11-28 | 2002-06-06 | Mondobiotech Sa | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
US20030096748A1 (en) * | 2001-06-04 | 2003-05-22 | The Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
US7074893B2 (en) * | 2002-06-03 | 2006-07-11 | Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
JP2011526303A (ja) | 2008-06-27 | 2011-10-06 | デューク ユニバーシティ | エラスチン様ペプチドを含む治療剤 |
PT2464370T (pt) * | 2009-08-14 | 2017-05-17 | Phasebio Pharmaceuticals Inc | Péptidos vasoativos intestinais modificados |
WO2012170524A1 (en) | 2011-06-06 | 2012-12-13 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
EP3139949B1 (de) | 2014-05-08 | 2020-07-29 | Phasebio Pharmaceuticals, Inc. | Zusammensetzungen enthaltend ein vip-elp fusionsprotein zur verwendung in der behandlung von mukoviszidose |
JP6824888B2 (ja) | 2015-02-09 | 2021-02-03 | フェーズバイオ ファーマシューティカルズ,インコーポレイテッド | 筋肉の疾患および障害を治療するための方法および組成物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3879371A (en) * | 1971-09-17 | 1975-04-22 | Sami I Said | Isolation of vasoactive intestinal peptide |
FR2308266A1 (fr) * | 1975-04-18 | 1976-11-12 | Telecommunications Sa | Procede de transmission dans des reseaux de connexion temporels a grande capacite |
DE3064888D1 (en) * | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
JPS56128721A (en) * | 1980-03-12 | 1981-10-08 | Eisai Co Ltd | Antiallergic agent |
US4605641A (en) * | 1984-10-09 | 1986-08-12 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
GB8427651D0 (en) * | 1984-11-01 | 1984-12-05 | Beecham Group Plc | Compounds |
JPS61118399A (ja) * | 1984-11-14 | 1986-06-05 | Otsuka Pharmaceut Co Ltd | ペプチドホルモンの製造法 |
GB8525852D0 (en) * | 1985-10-19 | 1985-11-20 | Beecham Group Plc | Compounds |
JPS62135407A (ja) * | 1985-12-10 | 1987-06-18 | Meiji Seika Kaisha Ltd | 育毛剤 |
JPS62246595A (ja) * | 1986-04-17 | 1987-10-27 | Eisai Co Ltd | 気菅支拡張作用・降圧作用ペプタイド |
US4853371A (en) * | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US4939224A (en) * | 1987-02-26 | 1990-07-03 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
SE8702520D0 (sv) * | 1987-06-16 | 1987-06-16 | Kabigen Ab | Mammal intestine hormone precursor |
US4935491A (en) * | 1987-08-24 | 1990-06-19 | Board Of Regents, The University Of Texas System | Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine |
US4935492A (en) * | 1987-12-24 | 1990-06-19 | California Biotechnology Inc. | Cyclic analogs of atrial natriuretic peptides |
-
1988
- 1988-07-08 IL IL8705588A patent/IL87055A/en not_active IP Right Cessation
-
1989
- 1989-07-07 US US07/376,559 patent/US5147855A/en not_active Expired - Lifetime
- 1989-07-07 EP EP89112463A patent/EP0354992B1/de not_active Expired - Lifetime
- 1989-07-07 AT AT89112463T patent/ATE120091T1/de active
- 1989-07-07 ES ES89112463T patent/ES2072875T3/es not_active Expired - Lifetime
- 1989-07-07 JP JP1176971A patent/JP2682702B2/ja not_active Expired - Fee Related
- 1989-07-07 DE DE68921814T patent/DE68921814T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0354992B1 (de) | 1995-03-22 |
JP2682702B2 (ja) | 1997-11-26 |
ES2072875T3 (es) | 1995-08-01 |
IL87055A0 (en) | 1988-12-30 |
DE68921814T2 (de) | 1995-09-28 |
JPH0276821A (ja) | 1990-03-16 |
US5147855A (en) | 1992-09-15 |
DE68921814D1 (de) | 1995-04-27 |
EP0354992A2 (de) | 1990-02-21 |
EP0354992A3 (de) | 1991-01-16 |
IL87055A (en) | 1994-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE120091T1 (de) | Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz. | |
SE8504945L (sv) | Farmaceutiska kompositioner innehallande antracyklinglykosider | |
ATE92080T1 (de) | Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15. | |
KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
PH23222A (en) | Immunoglobulin conjugates and pharmaceutical formulation thereof | |
DK0744957T3 (da) | Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A | |
EP0177342A3 (de) | Orale Formulierungen therapeutischer Proteine | |
DE69026269D1 (de) | Bioadhäsive zusammensetzung und pflaster | |
ATE60713T1 (de) | Pharmazeutische zusammensetzung aus guar-gummi und anderen antiacida zum schutz der oeso-gastro- duodenalen schleimhaut. | |
SE8800080D0 (sv) | Lekemedelskomposition | |
EP0230264A3 (en) | Pharmaceutical composition for nasal application, process for its preparation and its use | |
DK0773782T3 (da) | Terpenderivater (sarcodictyiner) anvendelse som antitumormidler | |
ES2016464A6 (es) | Procedimiento para preparar derivados de 2', 5' -oligoadenilato. | |
KR960705578A (ko) | 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease) | |
IT1206822B (it) | Derivati di glicina in qualita' di agenti preventivi e terapeutici del le complicanze diabetiche | |
DE69131517D1 (de) | Verwendung von Prostaglandin-E1 zur Behandlung männlicher erektiler Impotenz | |
DE69010523D1 (de) | Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen. | |
EA199900438A1 (ru) | Препарат местного применения для введения пептидных лекарственных средств в живые организмы | |
KR900017599A (ko) | 종양 치료용 약학 조성물 | |
TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
DE69313534D1 (de) | Digitoxigenin und Dihydrodigitoxigenin 3-beta-Derivate und pharmazeutische Präparate davon, zur Behandlung von hypertonie | |
DE3777411D1 (de) | Mittel zur verbesserung der perkutanen verabreichung von arzneimitteln. | |
KR890007737A (ko) | 진토작용을 하는 약제 | |
PT94787A (pt) | Processo de preparacao de composicoes farmaceuticas para administracao transdermica de corticosteroides e de compostos com actividade fisiologica semelhante | |
DE60217302D1 (de) | Erhaltung von körpereigenen proteinen |